Advancing Immuno‑Oncology Breakthroughs & Reducing Toxicity Risks Through Next‑Generation Preclinical Models

  • Gaining insights using cutting‑edge preclinical models to model toxicity mitigation strategies and on‑target/off‑tumor effects
  • Understanding optimized dosing strategies can expand therapeutic windows and improve the safety profile of next‑generation immunotherapies